Page 2 - ஃபார்மோஸ மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃபார்மோஸ மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃபார்மோஸ மருந்துகள் Today - Breaking & Trending Today

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, May 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2021. The full report can be accessed by clicking here.
Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: We continue to make good progress expanding our drug discovery business and remain well positioned to capitalize on a range of growth opportunities. We have initiated several exciting new technology collaborations designed to enhance our world-leading discovery platform and extend the reach of its application, including beyond GPCRs for the first time. We have made good progress with our partnered programs, which have delivered multiple milestones and generated ....

United Kingdom , Abbvie Allergan , Metrion Biosciences , Sosei Heptares , Hironoshin Nomura , Shinichi Tamura , Genentech Roche , Shinichiro Nishishita , Citigate Dewe Rogerson , Sosei Heptare , Sosei Group Corporation , International Media , Formosa Pharmaceuticals , Sosei Group , Sosei Group Corporation The Company , National Insurance , Tokyo Stock Exchange , Centessa Pharmaceuticals , Orexia Therapeutics , Initial Public Offering , Three Month Period , Corporate Strategy , Dewe Rogerson , David Dible , ஒன்றுபட்டது கிஂக்டம் , ஷினிச்சி தமுரா ,

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Share this article
Share this article
TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ( Formosa ) has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.
APP13007 was originally designed and developed at Activus Pharma Inc. ( Activus ), formerly a wholly owned subsidiary of the Company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a leading manufacturer of Active Pharmaceutical Ingredients ( APIs ) listed on the Taiwan Stock Exchange. The divestment was part of Sosei Heptares redirected ....

United Kingdom , United States , Prnewswire Sosei , Sosei Heptares , Hironoshin Nomura , Shinichi Tamura , States Clinicaltrials , Genentech Roche , Shinichiro Nishishita , Citigate Dewe Rogerson , Sosei Heptare , Sosei Group Corporation , International Media , Group Corporation The Company , Sosei Group , Tokyo Stock Exchange , Taiwan Stock Exchange , Activus Pharma Inc , Activus Pure Nanoparticle Technology , Formosa Laboratories Inc , Formosa Pharmaceuticals Inc , Group Corporation , Formosa Pharmaceuticals , Activus Pharma , Formosa Laboratories , Active Pharmaceutical Ingredients ,

Sosei : Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Sosei : Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Sosei Heptares , Activus Pharma , Hironoshin Nomura , Shinichi Tamura , States Clinicaltrials , Genentech Roche , Shinichiro Nishishita , Citigate Dewe Rogerson , Sosei Heptare , Sosei Group Corporation , International Media , Formosa Pharmaceuticals , Sosei Group , Sosei Group Corporation The Company , Tokyo Stock Exchange , Taiwan Stock Exchange , Activus Pharma Inc , Activus Pure Nanoparticle Technology , Formosa Laboratories Inc , Formosa Pharmaceuticals Inc , Group Corporation , Formosa Laboratories , Active Pharmaceutical Ingredients , Taiwan Stock ,